









Markets
/
Stocks
/
nasdaq-kprx
/

Kiora Pharmaceuticals Inc

KPRX

2.530USD

-0.121-4.55%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

8.69MMarket Cap

LossP/E TTM



Kiora Pharmaceuticals Inc

2.530

-0.121-4.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

206 / 506

Overall Ranking

331 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.000

Target Price

+315.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).

Growing

The company is in a growing phase, with the latest annual income totaling USD 16.02M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 3.59M.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is -0.75, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.51M shares, decreasing 17.01% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.08K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.23, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 3.11%.

Score

Industry at a Glance

Previous score

6.23

Change



Financials

7.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.93

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.42

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.79, which is -526.17% below the recent high of 3.36 and 2.13% above the recent low of -0.77.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 206/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Kiora Pharmaceuticals Inc is 11.00, with a high of 12.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.000

Target Price

+315.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Kiora Pharmaceuticals Inc

KPRX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 2.89, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.86 and the support level at 2.48, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.89

Change

-0.19

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.022

Sell

RSI(14)

39.581

Neutral

STOCH(KDJ)(9,3,3)

14.518

Sell

ATR(14)

0.116

Low Volatility

CCI(14)

-159.804

Sell

Williams %R

100.000

Oversold

TRIX(12,20)

-0.095

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.618

Sell

MA10

2.646

Sell

MA20

2.702

Sell

MA50

2.746

Sell

MA100

2.923

Sell

MA200

3.132

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 49.54%, representing a quarter-over-quarter increase of 6.69%. The largest institutional shareholder is The Vanguard, holding a total of 2.08K shares, representing 0.06% of shares outstanding, with 33.55% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Stonepine Capital Management, LLC

200.65K

-0.16%

Adar1 Capital Management LLC

194.66K

-2.77%

AIGH Capital Management, LLC.

159.11K

Velan Capital Investment Management LP

122.22K

Lincoln Park Capital, LLC

101.94K

+605.01%

Worth Venture Partners, LLC

94.44K

-2.07%

Strem (Brian M.)

46.10K

+53.24%

Nantahala Capital Management, LLC

211.11K

Daniels (Eric Joseph)

26.38K

+41.99%

Tosca (Melissa)

21.37K

+57.16%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.11, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.68. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.